| Timothy W Rogers, MD | |
|
2980 Se 3rd Ct, Ocala, FL 34471-0421 | |
| (352) 622-4231 | |
| (352) 622-0513 |
| Full Name | Timothy W Rogers |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 26 Years |
| Location | 2980 Se 3rd Ct, Ocala, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073511952 | NPI | - | NPPES |
| P00091569 | Other | FL | RRMC (IND) |
| CD4677 | Other | FL | RRMC (GRP) |
| 266957900 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | ME85781 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vascular Action, Llc | 0840427746 | 2 |
| Ocala Kidney Group Inc | 5092795054 | 13 |
News Archive
In a study that investigates the challenges of disseminating clinical research findings in peer-reviewed biomedical journals, Yale School of Medicine researchers have found that fewer than half of a sample of trials primarily or partially funded by the National Institutes of Health (NIH) were published within 30 months of completing the clinical trial.
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans.
InterSystems Corporation, the global leader in software for connected healthcare, today announced that InterSystems Ensemble® was the software platform for the first-ever successful electronic transmission of comprehensive genetic data. The information was sent cross-country from Boston-based Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) to Intermountain HealthCare in Salt Lake City, Utah. The announcement about reaching this milestone in personalized medicine came at the HIMSS10 conference.
The U.S. Food and Drug Administration has been investigating reports that patients undergoing computed tomography (CT) brain perfusion scans were accidently exposed to excess radiation. The FDA found that when properly used, the CT scanners did not malfunction. Instead, it is likely that the improper use of the scanners resulted in these overdoses. However, the FDA has identified a series or promising steps to enhance the safety of these procedures. These steps could reduce the likelihood of radiation overexposure in the event of improper use of the CT scanners.
› Verified 3 days ago
| Entity Name | Ocala Kidney Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407891898 PECOS PAC ID: 5092795054 Enrollment ID: O20040721001233 |
News Archive
In a study that investigates the challenges of disseminating clinical research findings in peer-reviewed biomedical journals, Yale School of Medicine researchers have found that fewer than half of a sample of trials primarily or partially funded by the National Institutes of Health (NIH) were published within 30 months of completing the clinical trial.
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans.
InterSystems Corporation, the global leader in software for connected healthcare, today announced that InterSystems Ensemble® was the software platform for the first-ever successful electronic transmission of comprehensive genetic data. The information was sent cross-country from Boston-based Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) to Intermountain HealthCare in Salt Lake City, Utah. The announcement about reaching this milestone in personalized medicine came at the HIMSS10 conference.
The U.S. Food and Drug Administration has been investigating reports that patients undergoing computed tomography (CT) brain perfusion scans were accidently exposed to excess radiation. The FDA found that when properly used, the CT scanners did not malfunction. Instead, it is likely that the improper use of the scanners resulted in these overdoses. However, the FDA has identified a series or promising steps to enhance the safety of these procedures. These steps could reduce the likelihood of radiation overexposure in the event of improper use of the CT scanners.
› Verified 3 days ago
| Entity Name | Ocala Kidney Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407891898 PECOS PAC ID: 5092795054 Enrollment ID: O20090914000526 |
News Archive
In a study that investigates the challenges of disseminating clinical research findings in peer-reviewed biomedical journals, Yale School of Medicine researchers have found that fewer than half of a sample of trials primarily or partially funded by the National Institutes of Health (NIH) were published within 30 months of completing the clinical trial.
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans.
InterSystems Corporation, the global leader in software for connected healthcare, today announced that InterSystems Ensemble® was the software platform for the first-ever successful electronic transmission of comprehensive genetic data. The information was sent cross-country from Boston-based Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) to Intermountain HealthCare in Salt Lake City, Utah. The announcement about reaching this milestone in personalized medicine came at the HIMSS10 conference.
The U.S. Food and Drug Administration has been investigating reports that patients undergoing computed tomography (CT) brain perfusion scans were accidently exposed to excess radiation. The FDA found that when properly used, the CT scanners did not malfunction. Instead, it is likely that the improper use of the scanners resulted in these overdoses. However, the FDA has identified a series or promising steps to enhance the safety of these procedures. These steps could reduce the likelihood of radiation overexposure in the event of improper use of the CT scanners.
› Verified 3 days ago
| Entity Name | Vascular Action, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871921163 PECOS PAC ID: 0840427746 Enrollment ID: O20131223000726 |
News Archive
In a study that investigates the challenges of disseminating clinical research findings in peer-reviewed biomedical journals, Yale School of Medicine researchers have found that fewer than half of a sample of trials primarily or partially funded by the National Institutes of Health (NIH) were published within 30 months of completing the clinical trial.
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans.
InterSystems Corporation, the global leader in software for connected healthcare, today announced that InterSystems Ensemble® was the software platform for the first-ever successful electronic transmission of comprehensive genetic data. The information was sent cross-country from Boston-based Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) to Intermountain HealthCare in Salt Lake City, Utah. The announcement about reaching this milestone in personalized medicine came at the HIMSS10 conference.
The U.S. Food and Drug Administration has been investigating reports that patients undergoing computed tomography (CT) brain perfusion scans were accidently exposed to excess radiation. The FDA found that when properly used, the CT scanners did not malfunction. Instead, it is likely that the improper use of the scanners resulted in these overdoses. However, the FDA has identified a series or promising steps to enhance the safety of these procedures. These steps could reduce the likelihood of radiation overexposure in the event of improper use of the CT scanners.
› Verified 3 days ago
| Entity Name | Melvin M. Seek, Md, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043756539 PECOS PAC ID: 0749565281 Enrollment ID: O20170323000874 |
News Archive
In a study that investigates the challenges of disseminating clinical research findings in peer-reviewed biomedical journals, Yale School of Medicine researchers have found that fewer than half of a sample of trials primarily or partially funded by the National Institutes of Health (NIH) were published within 30 months of completing the clinical trial.
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans.
InterSystems Corporation, the global leader in software for connected healthcare, today announced that InterSystems Ensemble® was the software platform for the first-ever successful electronic transmission of comprehensive genetic data. The information was sent cross-country from Boston-based Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) to Intermountain HealthCare in Salt Lake City, Utah. The announcement about reaching this milestone in personalized medicine came at the HIMSS10 conference.
The U.S. Food and Drug Administration has been investigating reports that patients undergoing computed tomography (CT) brain perfusion scans were accidently exposed to excess radiation. The FDA found that when properly used, the CT scanners did not malfunction. Instead, it is likely that the improper use of the scanners resulted in these overdoses. However, the FDA has identified a series or promising steps to enhance the safety of these procedures. These steps could reduce the likelihood of radiation overexposure in the event of improper use of the CT scanners.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Timothy W Rogers, MD 2980 Se 3rd Ct, Ocala, FL 34471-0421 Ph: (352) 622-4231 | Timothy W Rogers, MD 2980 Se 3rd Ct, Ocala, FL 34471-0421 Ph: (352) 622-4231 |
News Archive
In a study that investigates the challenges of disseminating clinical research findings in peer-reviewed biomedical journals, Yale School of Medicine researchers have found that fewer than half of a sample of trials primarily or partially funded by the National Institutes of Health (NIH) were published within 30 months of completing the clinical trial.
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans.
InterSystems Corporation, the global leader in software for connected healthcare, today announced that InterSystems Ensemble® was the software platform for the first-ever successful electronic transmission of comprehensive genetic data. The information was sent cross-country from Boston-based Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) to Intermountain HealthCare in Salt Lake City, Utah. The announcement about reaching this milestone in personalized medicine came at the HIMSS10 conference.
The U.S. Food and Drug Administration has been investigating reports that patients undergoing computed tomography (CT) brain perfusion scans were accidently exposed to excess radiation. The FDA found that when properly used, the CT scanners did not malfunction. Instead, it is likely that the improper use of the scanners resulted in these overdoses. However, the FDA has identified a series or promising steps to enhance the safety of these procedures. These steps could reduce the likelihood of radiation overexposure in the event of improper use of the CT scanners.
› Verified 3 days ago
Joana Vicente Vargas, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3304 Se Lake Weir Ave, Ste 3, Ocala, FL 34471 Phone: 352-620-9181 Fax: 352-620-9193 | |
Dr. Sanjay A Patel, M.D. Nephrology Medicare: May Accept Medicare Assignments Practice Location: 419 Sw 15th St Ste 100, Ocala, FL 34471 Phone: 352-732-6400 Fax: 352-671-5283 | |
Dr. Kevin Jay Colver, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1500 Sw 1st Ave, Ocala, FL 34471 Phone: 352-671-2254 Fax: 352-671-2291 | |
Bhavani Ketheeswaran, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2810 Se 3rd Ct, Ocala, FL 34471 Phone: 352-732-0122 | |
Juan C Bustillo, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 3301 Sw 34th Cir Ste 101, Ocala, FL 34474 Phone: 352-861-0100 Fax: 352-861-1119 | |
Dr. Lon Helton Mcpherson, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 716 Se 36th Ln, Ocala, FL 34471 Phone: 352-553-5499 | |
Dr. Karthikram Komanduri, MD Nephrology Medicare: Medicare Enrolled Practice Location: 1431 Sw 1st Ave, Ocala, FL 34471 Phone: 352-401-8312 |